AMRI Announces Leadership Changes In Pharmaceutical Development And Manufacturing

ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ: AMRI) announced today that Steven R. Hagen, Ph.D. has been promoted to vice president of pharmaceutical development and manufacturing, reporting to AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D.

Previously, Dr. Hagen was vice president for quality and analytical chemistry and was responsible for Analytical Chemistry, Quality Assurance and Regulatory Affairs for all AMRI locations. In this expanded role, he will additionally assume leadership for AMRI's Chemical Development, Small Scale cGMP Manufacturing, and Large Scale Commercial Manufacturing business components, including operations in Albany/Rensselaer and Syracuse, New York; Hyderabad, India; as well as AMRI's Large Scale Manufacturing operations in Rensselaer, New York and Aurangabad, India.

Dr. Hagen joined AMRI in 2005 as senior director of analytical quality services. Prior to AMRI, he spent over 10 years at Pfizer in positions of increasing responsibility culminating in director of analytical research and development at Pfizer's Global Research and Development Division. Before Pfizer, he managed the analytical activities at Ribi ImmunoChem Research, Inc. in support of R&D, production and quality control. Dr. Hagen earned a Ph.D. in biochemistry and a Master's degree in botany, both from the University of Idaho, as well as a B.A. in biology from Lawrence University.

Separately, Luckner G. Ulysse, Jr., Ph.D. has been promoted to vice president, chemical development from senior director, chemical development and small scale cGMP, reporting to Dr. Hagen. In addition to managing the company's small scale cGMP and chemical development operations including facilities in Albany/Rensselaer and Syracuse, New York, Dr. Ulysse will also integrate international development operations under his leadership, including AMRI operations in Hyderabad, India. Prior to joining AMRI in 1999, Dr. Ulysse was senior research chemist at Advanced ChemTech Inc. He earned a Ph.D. in organic and bio-organic chemistry from Purdue University.

Former vice president of pharmaceutical development and manufacturing, Jonathan D. Evans, will be leaving AMRI to pursue another career opportunity.

"We are pleased to announce the promotions of Drs. Hagen and Ulysse into these expanded leadership roles at AMRI," said AMRI Chairman, CEO and President Thomas E. D'Ambra, Ph.D. "Both of these individuals have consistently demonstrated the ability to achieve and deliver positive results from their teams and operations, as evidenced by the continued improvements to efficiencies and financial results in their departments. We believe they will continue to be drivers of successful change and growth. We wish both Drs. Hagen and Ulysse success in their new positions."

D'Ambra continued, "I'd also like to extend our thanks to Jonathan Evans for his contributions to the company, and wish him well in his future endeavors."

About AMRI

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

Forward-Looking Statements

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words and include, but are not limited to, statements by AMRI's Chairman, CEO and President and statements concerning the performance of the company's global chemistry platform. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission on March 17, 2008 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements

Copyright 2008 Business Wire All Rights Reserved.